In this guide
BPC-157 and TB-500 come up together so often that they're easy to lump into one category — "recovery peptides." But they are different molecules with different origins and different mechanisms in the research literature. Understanding the distinction matters if you're designing a study or deciding which to work with.
The short version: BPC-157 is a 15-amino-acid pentadecapeptide derived from a protective sequence in gastric juice, studied heavily in connective-tissue and gastrointestinal models. TB-500 is the synthetic full-length form of Thymosin Beta-4, a 43-amino-acid actin-regulating peptide, studied for cell migration, angiogenesis, and cardiac-tissue repair. They overlap in the broad theme of tissue repair but act through separate pathways.
What BPC-157 is studied for
BPC-157 appears in well over a hundred preclinical papers spanning tendon, ligament, muscle, bone, the GI lining, blood vessels, and nerve. Research has linked it to fibroblast outgrowth and migration in tendon-healing models,1 to growth-hormone-receptor expression in tendon fibroblasts,2 and to nitric-oxide-system signaling and gastrointestinal integrity — the setting in which it was originally described as a "stable gastric pentadecapeptide."3 Its defining feature in the literature is breadth: most peptides are characterized in one or two tissue systems, while BPC-157 has been examined across many.
What TB-500 is studied for
TB-500 is the synthetic form of Thymosin Beta-4, one of the most conserved actin-regulating peptides in nature, found in nearly every mammalian cell. Its research record centers on cell migration and tissue repair — accelerated re-epithelialization in dermal wound models,4 and roles in angiogenesis and endothelial migration.5 Where BPC-157 work emphasizes connective tissue and the GI tract, TB-500 work emphasizes actin dynamics, vascular formation, and cardiac tissue. Complementary themes, different molecular machinery.
Side-by-side comparison
| Property | BPC-157 | TB-500 |
|---|---|---|
| Type | Pentadecapeptide (15 aa) | Thymosin β4 synthetic (43 aa) |
| Origin | Gastric-juice protective sequence | Naturally occurring actin-regulating protein |
| Primary research focus | Connective tissue, GI integrity, angiogenesis | Cell migration, angiogenesis, cardiac tissue |
| Key mechanism themes | FAK-paxillin, nitric-oxide / VEGFR2 signaling | Actin binding (LKKTETQ), integrin-linked kinase / Akt |
| Often blended as | Wolverine (BPC-157 + TB-500), also in Glow and KLOW | |
Why they're studied together
Because their mechanisms are complementary rather than redundant, research protocols frequently pair them — BPC-157 contributing connective-tissue and NO-pathway effects, TB-500 contributing actin regulation and vascular/cell-migration effects. That pairing is exactly what the Wolverine blend provides in a single co-lyophilized vial, and both also appear in the multi-peptide Glow and KLOW blends. Studying them together lets researchers examine both axes under one reconstitution rather than juggling two vials.
Working with both? The Wolverine blend pairs BPC-157 and TB-500 at 10 mg each, third-party tested with a published COA.
View the Wolverine blendFrequently asked questions
Are BPC-157 and TB-500 the same thing? No. They are distinct peptides with different sequences, origins, and mechanisms. They are studied in overlapping tissue-repair contexts, which is why they're often mentioned together.
Can they be researched together? Yes — they're frequently studied as a pair, and the Wolverine blend combines them. Note that blends containing both are generally not recommended for research models involving anticoagulation.
Which has more published research? BPC-157 has the broader preclinical footprint across tissue types; Thymosin β4 / TB-500 has a deep record specifically in cell migration, angiogenesis, and cardiac repair. Both are well represented in peer-reviewed literature.
Research references
- Chang C-H, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol. 2011. PubMed ↗
- Chang C-H, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. PubMed ↗
- Sikirić P, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014. PubMed ↗
- Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. PubMed ↗
- Thymosin beta4 promotes angiogenesis, wound healing, and cell migration. Ann N Y Acad Sci. 2004. PubMed ↗
For in-vitro research and laboratory use only. Not for human consumption. References are provided for scientific context and do not constitute a product claim.